Kiniksa Pharmaceuticals International, plc (KNSA): Net Income
$59.01M
Year ended 2025-12-31
$73.06M
Trailing 12 months to 2026-03-31
-31.5%
3-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.01M | n/m | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | -$43.19M | n/m | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $14.08M | -92.3% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $183.36M | n/m | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | -$157.92M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$161.38M | n/m | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | -$161.87M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$103.23M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$64.87M | n/a | 2019-03-12, From 2017-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $59.01M | n/m |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$575.00M | n/m |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | -$38.55M | n/m |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$183.17M | n/m |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $98.09M | -38.5% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $7.03M | n/m |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $52.60M | n/m |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $447.18M | n/m |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$225.68M | n/m |
Compare KNSA, RARE, SUPN, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗